Clinical Trial Update: Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults [Phase 3]

View source ↗

Summary

A Phase 3 study comparing the immunogenicity, reactogenicity, and safety of GSK's HBV-MPL vaccine versus Engerix-B in adults with Hepatitis B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Engerix-B (hepatitis B vaccine)
• HBV-MPL vaccine (HBV-MPL vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED